Clinical Trial Update: The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing the effect of JNJ-39393406 on event-related potentials in stable schizophrenia patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Schizophrenia

Drugs mentioned

• JNJ-39393406

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Schizophrenia, Alzheimer's Disease | Phase 1 | Status: TERMINATED